Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioHarvest Sciences ( (BHST) ) has provided an announcement.
On March 26, 2026, BioHarvest Sciences reported that its VINIA brand has become the No. 1 resveratrol polyphenol nutraceutical brand in the United States by 2025 sales revenue, as measured against market estimates and major retail channels. Management links this leadership to VINIA’s clinically demonstrated ability to improve arterial dilation and blood flow, positioning the product as a differentiator in cardiovascular-focused wellness.
The company said VINIA’s direct-to-consumer model generated more than $30 million in U.S. revenue in 2025 and about $85 million in cumulative global sales, supported by over 85,000 active users in the U.S. and Israel. This performance underscores the commercial traction of BioHarvest’s Botanical Synthesis technology, strengthening its brand and technological credentials in plant-based health solutions and potentially enhancing its competitive standing in the broader nutraceuticals market.
The most recent analyst rating on (BHST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company specializing in its patented Botanical Synthesis platform, which grows plant-based molecules without cultivating the full plant. The Nasdaq- and Frankfurt-listed firm operates both as a contract development and production organization for complex plant-derived compounds and as a developer of proprietary nutraceutical and dietary supplement products, with a strong direct-to-consumer focus.
Average Trading Volume: 27,327
Technical Sentiment Signal: Buy
Current Market Cap: $97.87M
For an in-depth examination of BHST stock, go to TipRanks’ Overview page.